Patients lost about 9% of body weight at 40 weeks in a 448 person trial, with fewer stomach side effects than Wegovy. Hanmi promises a lower price.
Recap by typeshit. Full story at Korea JoongAng Daily.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
Visitors to Japan pay roughly a third of the Korean price for Mounjaro, and Korean customs says illegal imports of the drug are rising sharply this year.
Novo's preprint covers 10,052 trial patients and ties semaglutide to organ ages one to four years younger, but none of it is peer reviewed yet.
Loading…